Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 55, Issue 11, Pages 1121-1126Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.10.042
Keywords
pediatrics; hypercholesterolemia; drugs; genetics; prevention
Categories
Funding
- AstraZeneca
- Bristol-Myers Squibb
- Genzyme
- Merck Sharp and Dohme
- Pfizer
- Schering-Plough
- Roche
- Novartis
- Merck
- Merck-Schering-Plough
- Isis
- Sanofi-Aventis
Ask authors/readers for more resources
Objectives This study was undertaken to evaluate the efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. Background Familial hypercholesterolemia is a common inherited disorder causing markedly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth and resulting in premature atherosclerosis. In children, statins have been shown to be effective in reducing LDL-C, restoring flow-mediated dilation, and slowing carotid intima-media thickening. However, few children in these trials achieved current LDL-C goals. Methods This study comprised a 12-week double-blind, randomized, placebo-controlled trial, followed by a 40-week openlabel, titration-to-goal extension phase in 177 pubertal children, ages 10 to 17 years, with familial hypercholesterolemia. Participants were randomly assigned to placebo or rosuvastatin 5, 10, or 20 mg once daily. Results Compared with placebo, rosuvastatin 5, 10, and 20 mg reduced LDL-C by 38%, 45%, and 50%, respectively (p < 0.001 for each group vs. placebo). With a maximum allowed dose of 20 mg, 40% achieved the treatment goal of <110 mg/dl during the open-label, titration-to-goal phase. Rosuvastatin was well tolerated, with no apparent adverse impact on growth or development. Conclusions In children with familial hypercholesterolemia, rosuvastatin 20 mg daily reduced LDL-C by 50%. Nonetheless, only 40% attained the consensus LDL-C target of <110 mg/dl, reflecting these patients' high baseline LDL-C levels (mean, 232 mg/dl). (Pediatric Lipid-Reduction Trial of Rosuvastatin [PLUTO]; NCT00355615) (J Am Coll Cardiol 2010;55:1121-6) (C) 2010 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available